Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vistagen Therapeutics Inc
(NQ:
VTGN
)
3.650
+0.050 (+1.39%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Vistagen Therapeutics Inc
< Previous
1
2
3
4
5
6
Next >
BioMedNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases Q1 2025 Financial, Corporate Report
August 14, 2024
Via
Investor Brand Network
Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update
August 13, 2024
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Schedules Release of Q1 2025 Results, Conference Call
August 06, 2024
Via
Investor Brand Network
Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024
August 06, 2024
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Awarded New Patents from Four Countries to Broaden Global PH80 IP Portfolio
July 09, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine
July 09, 2024
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Receives Mental Health America’s Highest Honor
June 27, 2024
Via
Investor Brand Network
Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year
June 27, 2024
From
Vistagen
Via
Business Wire
TinyGemsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases FY 2024 Financial Report, Corporate Update
June 12, 2024
Via
Investor Brand Network
Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
June 11, 2024
From
Vistagen
Via
Business Wire
BioMedNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Schedules FY 2024 Financial Results Report, Conference Call
June 07, 2024
Via
Investor Brand Network
Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024
June 07, 2024
From
Vistagen
Via
Business Wire
TinyGemsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) CEO to Present at Jefferies Global Healthcare Conference
May 29, 2024
Via
Investor Brand Network
Vistagen to Present at the Jefferies Global Healthcare Conference
May 29, 2024
From
Vistagen
Via
Business Wire
BioMedNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Present Posters at Upcoming ASCP Conference
May 23, 2024
Via
Investor Brand Network
Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference
May 23, 2024
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Present at Upcoming RBC Capital Markets Global Healthcare Conference
May 07, 2024
Via
Investor Brand Network
Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference
May 07, 2024
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Reports Positive PH15 Data from Pilot Study Showing Psychomotor Impairment Improvement
April 25, 2024
Via
Investor Brand Network
Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
April 25, 2024
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation at Upcoming Anxiety and Depression Association Conference
April 09, 2024
Via
Investor Brand Network
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
April 09, 2024
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Appointment of New VP of Translational Medicine
April 01, 2024
Via
Investor Brand Network
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
April 01, 2024
From
Vistagen
Via
Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc.’s (NASDAQ: VTGN) Announces Participation at Upcoming Stifel 2024 Virtual CNS Days
March 11, 2024
Via
Investor Brand Network
Vistagen to Present at Stifel 2024 Virtual CNS Days
March 11, 2024
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Present at TD Cowen Conference
February 28, 2024
Via
Investor Brand Network
Vistagen to Present at TD Cowen 44th Annual Health Care Conference
February 28, 2024
From
Vistagen
Via
Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc.’s (NASDAQ: VTGN) Releases Q3 2024 Financial Report, Corporate Update
February 14, 2024
Via
Investor Brand Network
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update
February 13, 2024
From
Vistagen
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.